Part 2 of the lecture about Cryo Immune Therapy given by Dr. Israel Barken from the Prostate Research and Education Foundation. Dr. Barken describes Cryo immunotherapy. The reasons why there are no consistent immune response after cryoablation are discussed. Suggestions for further research to enhance the cryoablation immune activation are brought up, based on pre clinical research on the subject. This is the second lecture to be followed up by further evidence of the cryo immunology phenomena.
Clinical Study Phase I Cryoimmunotherapy against Metastatic prostate Cancer Disease.
Dr. Israel Barken, the Medical Director of the Prostate Cancer Research and Education, presents a clinical study phase I, featuring cryosurgery plus immuno-Modulator – Cyclophosphamide and Anti CTLA 4 Antibodies- Ipilimumab (Yervoy)
Active Surveillance In Intermediate-Risk Prostate Cancer Called Into Question.
Dr. Israel Barken brings info about higher risk of cancer specific mortality in the intermediate prostate cancer risk group. The study presentor at the GenitoUrinary Symposium 2015 was Dr. Andrew Loblaw. The study was conducted at the Sunnybrook Health Sciences Center. The risk of prostate cancer-specific death at 15 years was 3.75 times higher for intermediate risk patients compared to patients with low risk patients.
Source: ASCO POST March , 2015
Testosterone and the risk of cancer.
Dr. Israel Barken , the medical director of the prostate cancer research and education foundation PCREF discusses a recent article in the BJU Int. 2015 Feb;115(2):317-21..
Testosterone therapy and cancer risk.
Eisenberg ML1, Li S, Betts P, Herder D, Lamb DJ, Lipshultz LI
Circulating Epithelial Tumor Cells (CETC) and Tumor Spheres.
Discussion with Prof. Katharina Pachmann, Ph.D, M.D who is the medical Doctor in Jena University Hopital’s Department of Experimental Hematology and Oncology. She is an expert on Circulating Epithelial Tumor Cells.
The role of CETC in monitoring cancer and its use for Chemo sensitivity was discussed.
A SUBPOPULATION AMONG CIRCULATING EPITHELIAL TUMOR CELLS IN PATIENTS WITH SOLID CANCER IS CAPABLE OF SPHERE FORMATION AND CARRIES CANCER STEM CELL PROPERTIES.
For more information Please visit www.maintrac.com
Or write to Info@PCREF.org
Prostvac in Preventing Disease Progression in Patients with Localized Cancer Undergoing Active Surveillance.
What is unique about this vaccine study , is the fact that it is given to patients with localized disease. Practically, the patient gets a series of vaccination injected under the skin.
Click here to send a video question and you will get an e mail video reply
Liquid Biopsy – The Role of Exosomes. Dr. Israel Barken introduces the videos published by Life Technologies from ThermoFisher Technologies. The introduction relates to the importance of using imaging and markers to define recurrent disease and monitor the progression. The ability to harvest Tumor Cells, Free Tumor Cells DNA, MicroRNA from the blood, enables Genomic Interrogation of the tumor to assess prognosis, assist in follow up and create a personalized approach to the patient.
What is Exosome?
The History and Promise of Exosomes
Exosome in Cancer Research